• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial
Summary Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long‐term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alone or in combination with a platelet P2Y12 inhibitor (dual antiplatelet therapy [DAPT]) has become the clinically accepted antithrombotic prophylaxis for patients post‐ACS. Historically, studies assessing the utility of adding oral anticoagulants (OACs) have not demonstrated a clinical benefit with regard to acceptabl...
Source: Cardiovascular Therapeutics - September 9, 2014 Category: Cardiology Authors: Marc Cohen, Deepa Iyer Tags: Review Source Type: research

The ‘Dual‐Pathway’ Strategy After Acute Coronary Syndrome: Rivaroxaban and Anti‐platelet Agents in the ATLAS ACS 2‐TIMI 51 Trial
This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - June 1, 2014 Category: Cardiology Authors: Marc Cohen, Deepa Iyer Tags: Unsolicited Review Source Type: research

Dipeptidyl peptidase‐4 inhibitors and cardiovascular outcomes: Meta‐analysis of randomized clinical trials with 55,141 participants
ConclusionThese findings suggest no cardiovascular harm (or benefit) with DPP‐4 inhibitors; further large‐scale CV outcome studies will resolve the issue of excess HF risk.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - April 1, 2014 Category: Cardiology Authors: Shiying Wu, Ingrid Hopper, Marina Skiba, Henry Krum Tags: Original Research Article Source Type: research

Bivalirudin use and one‐month outcome in the context of contemporary antiplatelet treatment: Insights from the Greek Antiplatelet Registry
ConclusionsIn a ‘real life’, contemporary antiplatelet treatment registry, clinical, laboratory and logistic factors affect bivalirudin's choice, while there are no differences in one‐month outcome between bivalirudin and no bivalirudin treated patients.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - February 1, 2014 Category: Cardiology Authors: Dimitrios Alexopoulos, Ioanna Xanthopoulou, Spyridon Deftereos, George Sitafidis, Ioannis Kanakakis, Michalis Hamilos, George Karayannis, Christos Angelidis, Katerina Stavrou, Manolis Vavuranakis, John A. Goudevenos, Christodoulos Stefanadis, Tags: Original Research Article Source Type: research

Xanthine Oxidase Inhibition for the Treatment of Cardiovascular Disease: A Systematic Review and Meta‐Analysis
This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - December 1, 2013 Category: Cardiology Authors: J Zhang, R Dierckx, JG Cleland Tags: Letter Source Type: research

Practical Considerations in the Use of Novel Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation
This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - October 1, 2013 Category: Cardiology Authors: Steven Deitelzweig Tags: Unsolicited Review Source Type: research

Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy
ConclusionsIschemic stroke and intestinal bleeding may consecutively occur shortly after stopping dabigatran. Coagulation parameters may remain abnormal even two days after discontinuation of dabigatran. Dabigatran should be applied with caution in elderly patients with renal insufficiency who also take drugs, which enhance the absorption of dabigatran.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - September 23, 2013 Category: Cardiology Authors: Josef Finsterer, Claudia Stöllberger, Gernot Paul, Adam Bastovansky Tags: Short Communication Source Type: research

Anticoagulation in Patients with Dilated Cardiomyopathy, Low Ejection Fraction, and Sinus Rhythm: Back to the Drawing Board
Summary Heart failure patients present an important thrombo‐embolic risk, including symptomatic or silent peripheral arterial embolism, pulmonary embolism, and stroke. Patients in sinus rhythm who have concomitant depressed (<35%) left ventricular ejection fraction have a 4% rate of embolic events. Several prospective randomized trials of anticoagulation in this group of patients were either underpowered or had a short period of follow‐up. Even though in two studies warfarin had a slight advantage over aspirin (in the WATCH and WARCEF trials), it was at the cost of an increased risk in major hemorrhage. To decrease ...
Source: Cardiovascular Therapeutics - September 12, 2013 Category: Cardiology Authors: Alexandru Nicolae Mischie, Valentin Chioncel, Ionel Droc, Crina Sinescu Tags: Short communication Source Type: research

Association Between Preoperative Diuretic Use and In‐hospital Outcomes After Cardiac Surgery
ConclusionPreoperative diuretics use is associated with an increased incidence of MAEs after cardiac surgery.© 2013 Blackwell Publishing Ltd
Source: Cardiovascular Therapeutics - March 20, 2013 Category: Cardiology Authors: Salman J. Bandeali, Waleed T. Kayani, Vei‐Vei Lee, MacArthur Elayda, Mahboob Alam, Henry D. Huang, James M. Wilson, Hani Jneid, Yochai Birnbaum, Anita Deswal, John Farmer, Christie M. Ballantyne, Salim S. Virani Tags: Original Research Article Source Type: research

Pages: 1  2  3